GYRE
GYRE THERAPEUTICS, INC.
+0.45 (+6.72%)7.15USD67.8K成交股數797M市值–本益比(近四季)6.8股價營收比-2.1%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 29.1M-2% | 22.5M+2% | 34.2M+34% | 30.6M+21% | 29.7M+9% | 22.1M-19% | 25.5M-20% | 25.2M-14% | 27.2M | 27.1M | 32.0M | 29.3M |
| 營業成本 | 2.2M | 1.2M | 1.7M | 1.6M | 1.2M | 894K | 958K | 770K | 979K | 1.3M | 1.2M | 1.1M |
| 毛利 | 26.9M+5% | 21.3M+1% | 35.5M+45% | 28.9M+18% | 25.6M-2% | 21.2M-18% | 24.5M-21% | 24.5M-13% | 26.2M | 25.9M | 30.9M | 28.3M |
| 毛利率 | 92.4% | 94.6% | 103.6% | 94.7% | 86.2% | 95.9% | 96.2% | 96.9% | 96.4% | 95.4% | 96.3% | 96.3% |
| 研發費用 | – | 6.7M | −111K | 2.4M | 8.4M | 3.1M | 2.8M | 3.4M | 2.2M | 4.6M | 3.0M | 3.6M |
| 銷售管理費用 | 7.9M | 7.2M | 4.3M | 4.3M | 7.3M | 5.0M | 3.8M | 3.4M | 3.4M | 10.1M | 1.2M | 1.7M |
| 營業利益 | −14.4M+541% | −9.4M-512% | 4.5M+7% | 6.9M+117% | −2.2M-128% | 2.3M-102% | 4.2M-67% | 3.2M-36% | 8.1M | −91.6M | 12.8M | 5.0M |
| 營業利益率 | -49.3% | -41.5% | 13.2% | 22.7% | -7.5% | 10.3% | 16.6% | 12.7% | 29.7% | -337.5% | 39.8% | 17.0% |
| 稅後淨利 | −14.3M+538% | −18.6M-476% | 1.2M-57% | 5.9M+31% | −2.2M-123% | 4.9M-105% | 2.9M-62% | 4.5M+20% | 9.9M | −101M | 7.5M | 3.8M |
| 淨利率 | -49.0% | -82.5% | 3.6% | 19.4% | -7.5% | 22.4% | 11.2% | 18.0% | 36.6% | -372.0% | 23.4% | 12.9% |
| 稀釋 EPS | -0.12+300% | -0.10 | 0.02+100% | 0.03+200% | -0.03-200% | 0.00-100% | 0.01-80% | 0.01-50% | 0.03 | -1.51 | 0.05 | 0.02 |
| 稀釋股數 | 101M | 91.3M | 103M | 104M | 89.2M | 102M | 103M | 102M | 103M | 65.8M | 78.9M | 78.9M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 43.3M | 37.5M | 49.2M | 40.4M | 36.5M | 15.0M | 15.9M | 16.1M | 29.8M | 33.5M | 2.2M | 6.9M |
| 應收帳款 | 27.8M | 22.8M | 31.1M | 25.9M | 24.6M | 20.2M | – | – | – | 15.2M | – | – |
| 存貨 | 11.4M | 11.4M | 10.2M | – | 8.9M | 7.9M | 6.4M | 5.6M | 4.9M | 4.3M | – | – |
| 總資產 | 199M | 162M | 220M | 159M | 153M | 130M | 125M | 121M | 122M | 117M | 10.0M | 12.4M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 34.3M | 25.0M | 31.4M | 22.0M | 23.2M | 25.5M | 26.8M | 27.6M | 33.2M | 38.1M | 6.4M | 7.4M |
| 股東權益 | 108M | 101M | 62.5M | 102M | 92.0M | 68.1M | 63.2M | 60.4M | 56.6M | −15.8M | 3.5M | −28.3M |
| 負債比 | 17.2% | 15.4% | 14.3% | 13.8% | 15.2% | 19.6% | 21.4% | 22.8% | 27.2% | 32.7% | 64.7% | 59.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 3.2M-2565% | – | – | – | −129K | – | – | 2.9M | – | – | – |
| 資本支出 | – | 178K | – | – | – | 122K | – | – | 231K | – | – | – |
| 自由現金流 | – | 3.0M-1296% | – | – | – | −251K | – | – | 2.7M | – | – | – |
| 折舊攤銷 | – | 672K | – | – | – | 535K | – | – | 415K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 13.3% | – | – | – | -1.1% | – | – | 9.8% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 117M
| Gyre Pharmaceuticals | 117M | 100.0% | +10.2% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 117M | +10.2% | 9.9M | 8.5% | 0.02 | −180K |
| FY2024 | 106M | -6.8% | 17.9M | 16.9% | 0.05 | −6.0M |
| FY2023 | 113M | +10.9% | −85.5M | -75.3% | -1.41 | 17.4M |
| FY2022 | 102M | +1294.0% | 4.3M | 4.2% | 0.03 | 5.7M |
| FY2021 | 7.3M | -65.0% | −87.9M | -1,198.3% | -2.87 | −84.6M |
| FY2020 | 20.9M | – | −56.2M | -268.5% | -2.93 | – |
| FY2019 | – | – | −55.2M | –% | -4.60 | −43.7M |
| FY2018 | 6K | – | −30.1M | -500,916.7% | -2.68 | −28.9M |